Evidence mapPaperPMID 37036635Full record

ArticleImmunologic research2023

Silencing ApoC3 alleviates LPS-induced acute lung injury by inhibiting TLR signaling pathway.

Yongjie Qi, Chen Chen, Xuejun Li, Yi Liu, Huiqin Qi, Yingchang Xue, Fengyong Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yongjie QiPulmonary and Critical Care Medicine, Jinan People's Hospital, Jinan, Shandong, 271199, People's Republic of China.
Chen ChenPulmonary and Critical Care Medicine, Jinan People's Hospital, Jinan, Shandong, 271199, People's Republic of China.
Xuejun LiPulmonary and Critical Care Medicine, Jinan People's Hospital, Jinan, Shandong, 271199, People's Republic of China.
Yi LiuPulmonary and Critical Care Medicine, Jinan People's Hospital, Jinan, Shandong, 271199, People's Republic of China.
Huiqin QiPulmonary and Critical Care Medicine, Jinan People's Hospital, Jinan, Shandong, 271199, People's Republic of China.
Yingchang XuePulmonary and Critical Care Medicine, Jinan People's Hospital, Jinan, Shandong, 271199, People's Republic of China.
Fengyong YangDepartment of Emergency, Jinan Key Laboratory of Acute Lung Injury Prevention and Treatment, Jinan Clinical Research Center of Respiratory Medicine, Jinan Clinical Research Center of Critical Care Medicine, Jinan People's Hospital, Jinan, 271199, Shandong, People's Republic of China. jnn6656@163.com.ORCID 0000-0003-1746-8235
Jinan City People's Hospital · CNFourth People’s Hospital of Jinan · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to confirm whether apolipoprotein C3 (ApoC3) can regulate the inflammatory response and tissue damage in acute lung injury (ALI) and explore its regulatory pathway. ALI mouse model was established by intraperitoneal injection of lipopolysaccharide (LPS). ApoC3 levels were detected by real-time quantitative polymerase chain reaction, immunohistochemistry, and western blot assays. The levels of various inflammatory factors were detected by enzyme-linked immunosorbent assay and western blot analysis. Finally, the expression of toll-like receptor (TLR)/nuclear factor kappa B (NF-κB) signaling pathway-related protein [TLR2, myeloid differentiation primary response protein 88 (MyD88), IL-1 receptor-associated kinase 1 (IRAK1), NF-κB p65, and inhibitor of kappa B alpha (IκBα)], SLP adaptor and CSK interacting membrane protein (SCIMP), spleen tyrosine kinase (Syk), and phosphorylated (p)-Syk was detected by western blot analysis. ApoC3 was overexpressed in ALI mouse lung tissue and cell inflammation model. Silencing ApoC3 reduced inflammatory factors and alleviated lung tissue damage in ALI mice. Silencing ApoC3 reduced inflammatory factors and downregulated the expression of TLR2, MyD88, IRAK1, NF-κB p65, and increased IκBα expression in LPS-treated RAW264.7 cells. Moreover, co-transfection of si-TLR2 and shApoC3 further enhanced the inhibitory effects on the levels of inflammatory factors induced by silencing ApoC3. ApoC3 overexpression increased the levels of inflammatory factors and protein expression of SCIMP and p-Syk, while silencing TLR2 reversed the promotive effects of ApoC3 overexpression on above factors. In LPS-induced ALI mouse model and inflammatory cell model, downregulation of ApoC3 reduced inflammatory factors and relieved tissue damage. This process might be achieved through the TLR pathway.

Indexed as

Acute Lung InjuryApolipoprotein C-IIINF-kappa BAnimalsDisease Models, AnimalLipopolysaccharidesLungMiceMyeloid Differentiation Factor 88NF-KappaB Inhibitor alphaSignal TransductionToll-Like Receptor 2Apolipoprotein C-IIILipopolysaccharidesMyeloid Differentiation Factor 88NF-kappa BNF-KappaB Inhibitor alphaToll-Like Receptor 2Acute lung injuryApoC3Inflammatory factorsTLR pathway

Identifiers

PMID37036635
OpenAlexW4362732979

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.